Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients

Cécile L. Tremblay; Danielle Rouleau; Claude Fortin; Emil Toma; Mohamed Sylla; Lise Cyr; Serge Cote; Mariana Baz; John Sampalis; Lydie Trautman; Rafick Pierre Sékaly; Guy Boivin

doi:10.1016/j.vaccine.2010.12.023

Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients

Cécile L. Tremblay, Danielle Rouleau, Claude Fortin, Emil Toma, Mohamed Sylla, Lise Cyr, Serge Cote, Mariana Baz, John Sampalis, Lydie Trautman, Rafick Pierre Sékaly, Guy Boivin

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

We evaluated the efficacy and tolerability of a single dose of the split virion AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in 84 HIV-1 infected individuals. Antibody titers were determined by hemagglutination inhibition assay and by microneutralization. Vaccine was well tolerated. At 21 days post vaccination, 56 (67%) patients had seroconverted. There was no correlation between baseline CD4 cell count (p = 0.539) or HIV viral load (p = 0.381) and immune response. Other vaccine strategies should be evaluated in this HIV population, to improve response rates.

Original language	English (US)
Pages (from-to)	1359-1363
Number of pages	5
Journal	Vaccine
Volume	29
Issue number	7
DOIs	https://doi.org/10.1016/j.vaccine.2010.12.023
State	Published - Feb 4 2011
Externally published	Yes

Keywords

Antibody response
H1N1
HIV
Hemaglutinin inhibition
Immunogenicity
Influenza
Microneutralization
Pandemic
Vaccine

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2010.12.023

Cite this

@article{1ed4bfba73dc4163a1f89aa74c85b3c2,

title = "Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients",

abstract = "We evaluated the efficacy and tolerability of a single dose of the split virion AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in 84 HIV-1 infected individuals. Antibody titers were determined by hemagglutination inhibition assay and by microneutralization. Vaccine was well tolerated. At 21 days post vaccination, 56 (67%) patients had seroconverted. There was no correlation between baseline CD4 cell count (p = 0.539) or HIV viral load (p = 0.381) and immune response. Other vaccine strategies should be evaluated in this HIV population, to improve response rates.",

keywords = "Antibody response, H1N1, HIV, Hemaglutinin inhibition, Immunogenicity, Influenza, Microneutralization, Pandemic, Vaccine",

author = "Tremblay, {C{\'e}cile L.} and Danielle Rouleau and Claude Fortin and Emil Toma and Mohamed Sylla and Lise Cyr and Serge Cote and Mariana Baz and John Sampalis and Lydie Trautman and S{\'e}kaly, {Rafick Pierre} and Guy Boivin",

note = "Funding Information: We would like to thank the patients who participated in this study, Genevi{\`e}ve B{\'e}langer-Jasmin for her administrative help; Denis Phaneuf, MD, Richard Morrisset, MD, Gr{\'e}goire No{\"e}l, MD, Michel Poisson, MD, Louise Labrecque, MD, Emil Toma, MD, and Chantal Beauvais and Marie-Christine Morin for their help in enrolling patients. This work was supported in part by CIHR grant # 209214 . CT is chercheur-boursier from the Fonds de Recherche en Sant{\'e} du Qu{\'e}bec and GB is the holder of the Canada research chair on emerging viruses and antiviral resistance. This work was supported by the Reseau FRSQ-SIDAMI. ",

year = "2011",

month = feb,

day = "4",

doi = "10.1016/j.vaccine.2010.12.023",

language = "English (US)",

volume = "29",

pages = "1359--1363",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "7",

}

TY - JOUR

T1 - Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients

AU - Tremblay, Cécile L.

AU - Rouleau, Danielle

AU - Fortin, Claude

AU - Toma, Emil

AU - Sylla, Mohamed

AU - Cyr, Lise

AU - Cote, Serge

AU - Baz, Mariana

AU - Sampalis, John

AU - Trautman, Lydie

AU - Sékaly, Rafick Pierre

AU - Boivin, Guy

N1 - Funding Information: We would like to thank the patients who participated in this study, Geneviève Bélanger-Jasmin for her administrative help; Denis Phaneuf, MD, Richard Morrisset, MD, Grégoire Noël, MD, Michel Poisson, MD, Louise Labrecque, MD, Emil Toma, MD, and Chantal Beauvais and Marie-Christine Morin for their help in enrolling patients. This work was supported in part by CIHR grant # 209214 . CT is chercheur-boursier from the Fonds de Recherche en Santé du Québec and GB is the holder of the Canada research chair on emerging viruses and antiviral resistance. This work was supported by the Reseau FRSQ-SIDAMI.

PY - 2011/2/4

Y1 - 2011/2/4

N2 - We evaluated the efficacy and tolerability of a single dose of the split virion AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in 84 HIV-1 infected individuals. Antibody titers were determined by hemagglutination inhibition assay and by microneutralization. Vaccine was well tolerated. At 21 days post vaccination, 56 (67%) patients had seroconverted. There was no correlation between baseline CD4 cell count (p = 0.539) or HIV viral load (p = 0.381) and immune response. Other vaccine strategies should be evaluated in this HIV population, to improve response rates.

AB - We evaluated the efficacy and tolerability of a single dose of the split virion AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in 84 HIV-1 infected individuals. Antibody titers were determined by hemagglutination inhibition assay and by microneutralization. Vaccine was well tolerated. At 21 days post vaccination, 56 (67%) patients had seroconverted. There was no correlation between baseline CD4 cell count (p = 0.539) or HIV viral load (p = 0.381) and immune response. Other vaccine strategies should be evaluated in this HIV population, to improve response rates.

KW - Antibody response

KW - H1N1

KW - HIV

KW - Hemaglutinin inhibition

KW - Immunogenicity

KW - Influenza

KW - Microneutralization

KW - Pandemic

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=79151472358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79151472358&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.12.023

DO - 10.1016/j.vaccine.2010.12.023

M3 - Article

C2 - 21185423

AN - SCOPUS:79151472358

SN - 0264-410X

VL - 29

SP - 1359

EP - 1363

JO - Vaccine

JF - Vaccine

IS - 7

ER -

Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this